Ascentage Pharma's Pipeline Shines at AACR 2025: Five Preclinical Studies Unveiled

Ascentage Pharma, a global biopharmaceutical company, is set to make waves at the 2025 American Association of Cancer Research (AACR) Annual Meeting. The company will present five preclinical studies highlighting the latest advancements from its innovative pipeline. These studies, scheduled for April 25-30, 2025, in Chicago, Illinois, showcase Ascentage Pharma's commitment to addressing unmet medical needs, particularly in hematological malignancies.

The AACR Annual Meeting is a pivotal event in the cancer research community, bringing together scientists, clinicians, and advocates to share and discuss the latest breakthroughs. Ascentage Pharma's participation underscores the significance of its preclinical data and the potential impact of its drug candidates on cancer treatment.



One of the key highlights is the combination of olverembatinib (HQP1351) and lisaftoclax (APG-2575), which has shown promising results in overcoming venetoclax resistance in preclinical models of acute myeloid leukemia (AML). This combination therapy represents a significant advancement in the treatment of AML, a disease with high unmet medical needs. The data presented at the AACR Annual Meeting will provide insights into the mechanisms behind this resistance and the potential of this combination therapy to improve patient outcomes.

Another notable study focuses on the effects of olverembatinib in combination with lisaftoclax in T-cell acute lymphoblastic leukemia (T-ALL). This study highlights the potential of this combination therapy to target multiple pathways in cancer cells, enhancing its antitumor activity. The preclinical data suggests that this combination could be a game-changer in the treatment of T-ALL, a rare but aggressive form of leukemia.

Ascentage Pharma's pipeline also includes APG-5918, an EED inhibitor that exhibits potent antitumor activity and synergizes with enzalutamide in preclinical prostate cancer models. This study underscores the potential of epigenetic targets in cancer treatment and the importance of combination therapies in enhancing antitumor activity. The data presented at the AACR Annual Meeting will provide valuable insights into the mechanisms behind this synergy and the potential of APG-5918 as a novel therapeutic option for prostate cancer.

APG-2449, a novel focal adhesion kinase (FAK) inhibitor, is another promising drug candidate in Ascentage Pharma's pipeline. Preclinical studies have shown that APG-2449 enhances the antitumor activity of chemotherapy in small-cell lung cancer (SCLC) models with activated FAK. This study highlights the potential of FAK inhibitors in combination with chemotherapy to improve treatment outcomes in SCLC, a disease with limited therapeutic options.

Finally, Ascentage Pharma will present data on AS03157, a highly potent and orally active antagonist of inhibitor of apoptosis proteins (IAPs). This study showcases the potential of IAP antagonists as a novel therapeutic approach in cancer treatment. The preclinical data suggests that AS03157 could be a promising candidate for further development, offering a new avenue for targeting apoptosis in cancer cells.



The presentation of these five preclinical studies at the AACR Annual Meeting 2025 is a testament to Ascentage Pharma's commitment to innovation and its dedication to addressing unmet medical needs in cancer treatment. The company's diverse pipeline and its focus on targeting key apoptosis regulators position it as a leader in the biopharmaceutical industry. As the AACR Annual Meeting approaches, all eyes will be on Ascentage Pharma as it unveils the latest advancements from its innovative pipeline.